PETCT Imaging Using 68Ga-ICAM-1pep to Monitor Tumor Response to Radiotherapy in Adults with Cancer

What this Trial Is About

This research aims to evaluate the use of a new imaging agent called 68Ga-ICAM-1pep in cancer patients undergoing radiotherapy. Researchers want to see if this agent can help predict the abscopal effect, a phenomenon where radiotherapy affects tumors outside the treated area. The study focuses on patients with various cancers such as lung, esophagus, and cervical cancer, and it is an early-phase clinical trial investigating this new approach. Participants will receive a single intravenous dose of 2.96 MBqkg of 68Ga-ICAM-1pep. PETCT scans will be performed about one hour after the injection. There are two groups patients who have not yet received radiotherapy and those who have completed radiotherapy. Imaging will be done before and during radiotherapy to observe tumor responses. During the study, participants will undergo PETCT scans covering from the head to the upper thigh. Researchers will measure the standardized uptake values SUVs of 68Ga-ICAM-1pep before treatment and monitor changes during radiotherapy, about 3 to 4 weeks after it begins. The study includes monitoring for compliance with imaging procedures and overall safety until the study ends in late 2025.

68Ga-ICAM-1pep PET/CT in Cancer Patients